

ASX ANNOUNCEMENT

30 November 2011

Results of Annual General Meeting

The Annual General Meeting of the Company was held at the 77 St Georges Terrace, Perth Western Australia, on Wednesday 30 November 2011 at 10.00am.

The resolutions voted on were in accordance with the Notice of Annual General Meeting previously released to the ASX and mailed to shareholders.

In accordance with Section 251AA of the *Corporations Act 2001*, the following information is also provided:

Resolution		Result	Number of Proxy Votes			
			For	Against	Abstain	Proxy's Discretion
1.	Remuneration Report (non-binding)	Passed on a show of hands	7,066,760	810,440	15,743,338	202,059
2.	Re-election of Director Mr Graham Dowland	Passed on a show of hands	15,505,764	750,000	7,364,774	202,059

Yours sincerely
IMUGENE LIMITED

Julie Foster
COMPANY SECRETARY

ABN 99 009 179 551

Registered Office
Level 20, Allendale Square, 77 St Georges Terrace, Perth WA 6000
Tel +61 8 9440 2660 Fax +61 8 9440 2699

www.imugene.com

About Imugene

Imugene Limited (ASX:IMU) specialises in the development of animal health products for pigs and poultry, including vaccines and productivity enhancers.

These biologically-based vaccines:

- Improve the health and welfare of pigs and poultry
- Reduce or eliminate the use of antibiotics, chemicals and drugs, and;
- Result in economic gains for the industries that use them.

Imugene's product portfolio targets a worldwide US\$3 billion animal health market and contains vaccines at each stage of the development process.

Constructed using Imugene's patented Porcine and Fowl Adenoviral Vector Delivery Systems, these vaccines address some of the major diseases and health issues threatening pig and poultry production worldwide, such as Porcine Reproductive and Respiratory Syndrome (PRRS), which causes losses of up to US\$1 billion every year.